Inspection readiness is the ability to withstand a regulatory inspection of a site at any time, without advance warning and without a scramble to pull records together. It means your quality systems, documentation, and personnel consistently meet the standard a regulator expects, as a matter of daily operation rather than a one-time exercise. The stakes are substantial: the MHRA completed 353 GMP inspections in 2024/25, the FDA issued 303 drug warning letters in FY2025 (a 59% year-on-year increase), and inspection outcomes range from a corrective action plan to a suspended manufacturing license.
Inspection readiness is a critical aspect of GxP compliance. It involves being prepared for regulatory inspections at all times, which is not just a requirement but a cornerstone of operational excellence. Key components of maintaining inspection readiness include:
A persistent misconception is that inspection readiness is something you activate a few weeks before an inspector is due to arrive. In practice, that never happens, as there is usually so little (or any) warning for when an inspection is about to take place. Both the MHRA and FDA conduct unannounced or short-notice inspections, particularly at sites with a history of findings or products flagged for supply risk. If readiness is treated as a periodic exercise, a short-notice visit finds an organization mid-scramble: overdue CAPAs closed in haste, training records backfilled, and staff briefed on talking points rather than genuinely familiar with their own processes.
The alternative is readiness as a continuous, embedded state. Picture two organizations. The first runs a readiness sprint ahead of every scheduled inspection: documentation gets tidied, staff get refreshed, and open CAPAs get closed out under time pressure. The second treats inspection readiness as inseparable from quality operations – audit trails are reviewed as part of routine work, CAPAs are closed on evidence rather than deadline, and any staff member can explain their process to a stranger at any time. Only the second organization is genuinely inspection-ready, because inspectors are testing whether the quality system works day to day, not whether it can be made to look good for two weeks.
Across MHRA and FDA enforcement patterns, six areas come up more consistently than any others. The table below gives a scannable reference; use it to benchmark your own program area by area.
Underneath all six areas sits the same underlying question: does this quality system work in practice, or does it only work on paper? Inspectors have shifted markedly from static document review toward operational effectiveness. Rather than confirming a CAPA procedure exists, an inspector will now ask, “show me evidence this CAPA was effective.” Rather than confirming an internal audit program is documented, they will ask, “show me your most recent internal audit report and the corrective actions taken.” Organizations that can answer both questions with evidence, not assurance, are the ones that pass.
GxP is not a single standard – it is a family of frameworks, each with its own inspection emphasis. QA teams operating across more than one discipline need to understand where those emphases diverge.
Organizations operating across multiple GxP areas carry an added burden: maintaining separate inspection-ready systems for each discipline. Cross-contamination between frameworks – for example, applying GMP-style change control where GCP requirements actually apply – is not a neutral shortcut. It is itself a finding.
Data integrity deserves its own section because it is not a marginal issue: it accounts for nearly 40% of all critical and major MHRA GMP deficiencies, and the trend has not reversed. Most QA professionals have heard of ALCOA+ without necessarily having a working definition to hand:
Each ALCOA+ principle translates directly into inspection risk. Take “contemporaneous”: a record created after the underlying activity took place is a critical finding regardless of whether the activity itself was performed correctly and on time. Good work, recorded late, is treated the same as work that was never verified at all.
For electronic systems specifically, inspectors focus on three recurring issues: audit trails that can be disabled or are not reviewed, shared user accounts that make it impossible to attribute an action to an individual, and gaps between electronic records and any parallel paper record. Closing these gaps starts with strong GMP documentation practices and extends to how audit trail data is monitored and acted on, not just retained.
An internal audit program is both a compliance requirement and the most reliable tool for staying ahead of external inspectors. An effective program has four components.
Inspectors routinely interview staff at every level, from operators on the production floor to the Qualified Person and site director. This matters because a well-documented system can still generate findings if the people running it cannot explain their own processes in their own words. Three aspects of preparation make the most difference.
GxP inspection readiness is a continuous state in which an organization’s quality systems, documentation, and personnel meet regulatory standards at all times, not just ahead of a scheduled visit. It reflects how well a quality system performs day to day, since MHRA and FDA inspections can occur with little or no advance notice.
MHRA inspectors focus on data integrity, CAPA effectiveness, change control, training records, the internal audit program, and documentation accuracy. They increasingly test whether these systems work operationally, not just whether they are documented on paper.
The most common findings involve data integrity gaps, weak root cause analysis in CAPAs, undocumented change control, and outdated training records. Data integrity issues alone account for nearly 40% of critical and major MHRA GMP deficiencies.
A mock inspection is a structured internal walkthrough that simulates a regulatory visit, including document requests and staff interviews. It surfaces gaps – in records, processes, or staff readiness – while there is still time to fix them before a real inspection.
Frequency should be risk-based rather than fixed. Higher-risk areas, such as sterile manufacturing or critical suppliers, typically warrant more frequent audits than lower-risk supporting functions, with the full audit program covering all GxP areas on a defined schedule.
Inspection readiness takes more than good intentions. It requires systems that surface potential issues before an inspector does, keep records genuinely audit-trail-ready, and give QA and GxP teams visibility across the full compliance program rather than a partial view of it. This might be for sites which you manage or which you outsource to CMO partners and vendors. Either way, QA and GxP teams are responsible for ensuring GxP compliance across the supply chain and making sure that there are no weak links where manufacturing is outsourced. Infodesk gives quality assurance and GxP teams that visibility: real-time inspection and enforcement intelligence on regulatory enforcement trends and inspection patterns, everything to prepare for regulatory inspections, respond to findings, and stay ahead of enforcement risk. The Infodesk I&E Intelligence solution is the only solution to turn I&E intelligence into action within a single platform that also monitors other enterprise intelligence streams and integrates with a workflow solution for immediate outcomes.
Inspection & enforcement intelligence. Activated.
Ready to strengthen your inspection readiness program? Book a meeting with Infodesk to see how.
Blogs
Read more
Webinars